Compass Pathways opened lower at $8.94, compared with its previous close of $9.30. In the last trading session, the stock traded between $8.85 and $9.34. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Compass Pathways is now worth
$ 26.49
Resulting in a loss of
$ 73.51 (73.51%)
Note: Past profits do not guarantee future returns.
Rating from 8 Analysts
Today's Change
$-0.17 (-1.87%)
Day High
$9.34
Day Low
$8.85
Day Open
$8.94
Prev Close
$9.30
Volume
20,93,215
1W Return
6.26%
1M Return
-20.90%
3M Return
-31.82%
6M Return
-5.43%
1Y Return
60.11%
Market Cap ($ Mn)
1,293
PE Ratio
-
PB Ratio
22.04
PEG Ratio
-
ROE
-289.33%
ROCE
-194.89%
EPS (TTM)
$-0.36
1 Week
6.26%
1 Month
-20.90%
3 Months
-31.82%
6 Months
-5.43%
9 Months
44.63%
Compass Pathways submits FDA NDA for psilocybin depression drug
Compass Pathways submitted an NDA to the FDA for COMP360 psilocybin targeting treatment-resistant depression. Submission relies on data from two Phase 3 trials and one Phase 2b study involving over 1,000 participants. All clinical programs met their primary endpoints with highly statistically significant results. Commercial launch is targeted for the first half of 2027, pending FDA approval and DEA rescheduling.
3 days agoBTIG reiterates Buy on Compass Pathways, maintains $25 target
BTIG analyst Thomas Shrader reiterated a Buy rating on Compass Pathways. The firm maintained its $25 price target for the stock. No changes were made to the existing valuation assumptions.
9 days agoCompass Pathways Q3 Results: EPS loss narrows to $0.31, beats estimate
Compass Pathways reported a Q3 loss of $0.31 per share. The result beat the consensus estimate of $0.43 by 27.91%. Losses narrowed by 18.42% compared to the same period last year.
9 days agoCompass Pathways appoints Kelley Boucher as chief people officer
Compass Pathways appointed Kelley Boucher as Chief People Officer effective immediately. Appointment supports transition from clinical-stage to commercial-stage operations. Boucher previously led people strategy at Apellis Pharmaceuticals and Alnylam Pharmaceuticals. Company targets NDA submission for COMP360 in Q4 2026 with potential launch in H1 2027.
1mo agoCompass Pathways to join TD Cowen neuropsychiatry summit fireside chat
Compass Pathways management to speak at TD Cowen summit on September 23, 2026. Fireside chat scheduled for 1:00 pm ET with live audio webcast access. Replay of the session will be available for 30 days post-event. Company focuses on COMP360 psilocybin for TRD and PTSD.
1mo agoCompath Pathways awards five US providers grants for COMP360 training
Compass Pathways awards five US providers grants for COMP360 training. Recipients retain control of content per ACCME standards. Program expanded from three to five due to applicant quality. Guidance documents available separately for healthcare providers.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $506.04 | +0.32% | $1,05,708.21M | 14.01 | |
| $304.77 | -0.26% | $49,345.01M | 45.36 | |
| $292.97 | +0.93% | $23,316.90M | 10.31 | |
| $72.62 | +0.18% | $14,450.29M | 52.31 | |
| $79.43 | -1.38% | $14,087.55M | - | |
| $142.24 | -0.19% | $13,957.16M | 20.21 | |
| $22.22 | -2.29% | $11,935.03M | 11.93 | |
| $183.50 | +2.35% | $11,542.15M | 15.26 | |
| $186.19 | +0.59% | $10,862.51M | 27.11 | |
| $196.77 | +0.70% | $10,170.65M | 7.00 | |
| $103.03 | -0.49% | $8,522.13M | 34.79 | |
| $50.06 | +1.96% | $7,945.72M | 25.00 |
An investment of $100 made 5 years ago in Compass Pathways is now worth
$ 26.49
Resulting in a loss of
$ 73.51 (73.51%)
Note: Past profits do not guarantee future returns.
